about   CII home   shop   checkout
Conference Banner

Pre-Conference Short Course

2013 Archived Content

Monday, August 12 • 2:00-5:00PM

Melanoma Biology and Immunotherapies  

Significant advances have been made in the understanding of the molecular underpinnings of melanoma development and progression and in elucidating the mechanisms by which these tumors escape immune surveillance. This session will address the current understanding of somatic genetic alterations that serve as the fundamental building blocks for malignant transformation in melanoma and as the basis for the first generation of molecular targeted therapies. Immune recognition of melanoma has been long recognized and underlies melanoma’s relatively unique responsiveness to cytokine-based immunotherapy. However, understanding of the negative immunomodulatory regulators that prevent elimination of melanoma has led to novel therapeutic approaches that manipulate effector antitumor T cell function.


Keith T. FlahertyKeith T. Flaherty, M.D., Associate Professor, Department of Medicine, Harvard Medical School; Director, Termeer Center for Targeted Therapy, Cancer Center, Massachusetts General Hospital






Jennifer Wargo, M.D., Surgical Oncologist, Massachusetts General Hospital; Instructor, Harvard Medical School


Dinner Short Course* 

Wednesday, August 14 • 6:30-9:30pm

Manufacturing Vaccines: New Approaches, New Technologies  

Novel vaccine production platforms are changing vaccines, affecting efficacy, and steering manufacturing away from egg-based production. This course will look at how vaccine production is being innovated, and how these innovations are affecting the way vaccines work. New technologies, such as cell culture-based production and using the BEVS (Baculovirus Expression Vector System), are opening the door to improved vaccines. Join us for this intimate discussion of how vaccine production is being revolutionized.

Topics to be discussed:

  • Cell culture-based production
  • Vaccine production in the BEVS
  • Vaccine production in non-egg-based systems
  • Production of new vaccine concepts
  • Optimized purification methods
  • Validated & controlled manufacturing


Sue Behrens, Ph.D., Consultant, Biologic, Vaccine & Sterile Products Manufacturing Technology, SB Executive Consulting, LLC; former Senior Director, Biological Sciences & Strategy, Vaccine & Sterile Operations, Merck

Todd Talarico, Ph.D., Vice President, Manufacturing, Medicago-USA


*Separate registration required

Download Conference & Course Catalog

CHI Catalog Cover